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ABSTRACT 
Neurodegeneration is the process of neuronal cell loss where the symptoms will reflect 
the regions affected. Neurodegenerative disorders including Alzheimer’s disease (AD), Parkin-
son’s disease (PD) and frontotemporal dementia (FTD) are all characterised by an accumulation 
of protein aggregates suggesting impaired production or turnover of these proteins. Hence, 
dysfunctional proteostasis is implicated in neurodegenerative disorders. In AD, there is a de-
creased turnover of endocytic and autophagic vesicles and an accumulation of endo-lysosomal 
proteins and ubiquitin in brain tissue. Lysosomal dysfunction has been indicated in PD by the 
link of disease risk and genetic alterations associated with lysosomal storage disorders as well as 
by decreased expression of lysosomal proteins in disease afflicted regions. Disease causing 
mutations and genetic risk factors in FTD suggest altered function of the autophagic and endo-
lysosomal system to be involved in the pathogenesis. 
The aim of this thesis was to examine dysfunctional proteostasis in neurodegenerative 
diseases by developing assays to monitor proteins from the autophagic and endo-lysosomal 
system and the ubiquitin-proteasome system in human cerebrospinal fluid (CSF). Proteins from 
the endo-lysosomal system and the ubiquitin-proteasome system have been identified and quan-
tified in CSF using mass spectrometry (MS)-based proteomics. Principally, three methods have 
been developed; 1) lysosomal membrane protein LAMP2 was purified from CSF by immuno-
precipitation followed by tryptic digestion and quantification by liquid chromatography (LC) 
and parallel reaction monitoring MS (PRM-MS); 2) full length ubiquitin was isolated from CSF 
by solid-phase extraction (SPE) followed by quantification by LC PRM-MS; and 3) finally, a 
panel of endo-lysosomal proteins, e.g., LAMP2, and ubiquitin, were analysed using tryptic 
digestion, peptide isolation by SPE and quantification by LC PRM-MS. CSF samples from 
cohorts including subjects with AD, PD, clinical FTD subtypes and FTD mutation carriers, as 
well as controls, were analysed with the developed assays. 
In AD the CSF levels of several endo-lysosomal proteins, including LAMP2, were ele-
vated compared to controls. CSF ubiquitin was also found to be elevated in AD compared to 
controls. In contrast, CSF levels of endo-lysosomal proteins and ubiquitin in PD were found to 
be decreased. Investigation in clinical subtypes of FTD and mutation carriers showed limited 
alterations in the CSF levels of endo-lysosomal proteins, suggesting dysfunctional proteostasis 
not to be readily detected in CSF in FTD. Our results showing altered CSF levels of proteins 
involved in proteostasis in AD and PD might indicate pathological alterations in the autophagic 
and endo-lysosomal system and the ubiquitin-proteasome system. Although further studies are 
needed, CSF ubiquitin in AD and endo-lysosomal proteins and ubiquitin in PD might serve as 
potential biomarkers in these disorders. 
Keywords: Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, dysfunctional 
proteostasis, cerebrospinal fluid, mass spectrometry 
